Graduated in Medicine in Hamburg, Germany. MD University of Hamburg. Basic Paediatric training in Lubeck, Germany, and Manchester. MRCP/MRCPH(UK) 1995. Higher Specialist Training in Paediatrics and Paedriatric Oncology in Manchester. Leukaemia Lymphoma Research Clinical Research Fellow 2000 – 2004, Paediatric Oncology, Manchester. PhD 2004, University of Manchester. CRUK Clinician Scientist 2005 -2010, University of Manchester .

Since 2010 Senior Lecturer / Honorary Consultant Paediatric Oncologist, Stem Cell and Leukaemia Proteomics Laboratory and clinically in the Department of Paediatric and Adoloscent Oncology of the University of Manchester at Royal Manchester Children’s and Christie Hospitals.

Collaborators and affiliated staff

Dr Meyer's laboratory work is carried out in the Stem Cell and Leukaemia Proteomics Laboratory headed by Professor Anthony D Whetton.

Dr Roberto Paredes  Postdoctoral Reseach Associate

Ms Hsiang Teng Research Assistant

Ms Marion Schneider PhD Student


Research interests

Stefan works as a Honorary Consultant Paediatric Oncologist at the Royal Manchester Children’s Hospital, where he also leads the multidisciplinary care for children with Fanconi anaemia, and the Young Oncology unit at the Christie Hospital.

Fanconi anaemia (FA) is an inherited disease with congenital and developmental abnormalities and extreme cancer predisposition. FA results from a defect a fundamental DNA damage response pathway with an important role in development, haematopoiesis and cancer prevention. Our research is focused on malignant transformation associated with FA, and functional aspects of the FA-pathway in sporadic cancers.

Using FA-derived AML cell lines we have identified amplification and overexpression of the EVI1 oncogene associated with FA characteristic gains in the chromosomal region 3q26q29. EVI1 is an oncogenic transcriptional regulator with a critical role in self renewal. EVI1 overexpression in AML, which is usually associated with balanced translocations confers poor prognosis in sporadic AML. EVI1 function and regulation is complex and includes transforming growth factor (TGF)-ß antagonistic and chromatin remodeling properties. We are exploring EVI1 function in the context of the FA defect.

Our FA-derived AML cell lines derived from the AML associated with bi-allelic disruption of the FANCD1/BRCA2 gene maintain the FA characteristic cross linker hypersensitivity. We explore the characteristics of the DNA damage response using systems biology approaches in order to identify regulatory events that might be therapeutically accessible.



Academic Lead - European Studies, Manchester Medical School

Firm Lead Paediatrics / Paediatic Oncology

Year 1 SSC supervsison

PhD, MPH and MRes supervision

Academic Advisor

Dr Meyer's Paediatic Oncology Clinic at RMCH can be booked via MedLea

ID: 596369